Novartis

Novartis's reported carbon emissions

**Novartis Carbon Emissions and Climate Commitments: A Summary** Headquartered in Switzerland and operating within the Pharmaceutical Preparation Manufacturing industry, Novartis has outlined significant carbon emission reduction targets and commitments. **Emissions Data:** In 2025, Novartis reported total global greenhouse gas emissions of approximately 4.38 billion kg CO2e. This figure breaks down into approximately 192.3 million kg CO2e for Scope 1, approximately 14.9 million kg CO2e for Scope 2 (market-based), and roughly 4.17 billion kg CO2e for Scope 3. The largest contributors to Scope 3 emissions in 2025 were purchased goods and services, accounting for approximately 3.23 billion kg CO2e, followed by upstream transportation and distribution at approximately 165 million kg CO2e. The previous year, 2024, saw total global emissions of approximately 4.52 billion kg CO2e. Scope 1 emissions were around 210.6 million kg CO2e, Scope 2 (market-based) were approximately 29.8 million kg CO2e, and Scope 3 emissions totalled approximately 4.28 billion kg CO2e. Similar to 2025, purchased goods and services represented the largest portion of Scope 3 emissions, at approximately 3.38 billion kg CO2e. For 2023, total global emissions were approximately 4.87 billion kg CO2e. This comprised about 251.1 million kg CO2e for Scope 1, approximately 44.1 million kg CO2e for Scope 2 (market-based), and roughly 4.57 billion kg CO2e for Scope 3. **Climate Commitments and Targets:** Novartis is committed to achieving net-zero greenhouse gas emissions across its value chain by 2040. As part of its near-term strategy, the company aims to reduce absolute Scope 1 and 2 greenhouse gas emissions by 90% by 2030, using a 2022 baseline. Additionally, Novartis is working to reduce absolute Scope 3 greenhouse gas emissions by 42% within the same 2030 timeframe. Further demonstrating its commitment to carbon neutrality, Novartis has set a target to become carbon neutral in its own operations (Scope 1 and 2) by 2025. This is aligned with the broader goal of achieving net-zero emissions across the value chain by 2040. The company has also committed to reducing absolute Scope 1 and 2 emissions by 90% from a 2022 base year by 2030, and maintaining at least a 90% reduction in Scope 1 and 2 emissions from 2030 through 2040. For Scope 3 emissions, the commitment is to reduce them by 90% by 2040 from a 2022 base year. Novartis has also engaged with initiatives such as the Science Based Targets initiative (SBTi), setting targets aligned with a 1.5°C pathway and committing to a 35% reduction in absolute Scope 1, 2, and 3 greenhouse gas emissions by 2030 from a 2016 baseline, classifying these as "Well-below 2°C" and "1.5°C" aligned. The company is also a signatory to the Climate Pledge.